{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:14:53Z","timestamp":1781939693242,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002954","name":"Universit\u00e0 degli Studi di Milano - Bicocca","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002954","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are critical regulators of renal development and function. Acromegaly, characterized by chronic GH hypersecretion, leads to renal hypertrophy and glomerular hyperfiltration. While immediate treatment of acromegaly mitigates hyperfiltration, the long-term risk of renal damage in treated patients remains unclear. Our study aimed to assess renal function over time in patients with acromegaly who were followed long-term at our institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study analyzed 80 patients with acromegaly from a single center. Creatinine values were recorded to assess kidney function before and after treatment. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI 2021 formula. eGFR variations were evaluated over the first 12 months after treatment (acute slope) and during long-term follow-up with a mean duration of 11.28 years (chronic slope). Descriptive statistics and multivariable regression analyses were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 80 patients (43.7 years, 46 male), 51 underwent surgery (11 of whom also received subsequent radiotherapy), while 29 received exclusively medical therapy. Comorbidities included diabetes (31.25%) and hypertension (65%). eGFR decreased acutely after treatment in all groups, with a more pronounced decline in surgically treated patients (mean \u2212\u200915.15 mL\/min\/1.73\u00a0m\u00b2; <jats:italic>p<\/jats:italic>\u2009=\u20090.042). The mean chronic eGFR loss was \u2212\u20091.28 mL\/year, with age (OR 1.09 per year) and diabetes (OR 5.66) significantly associated with a greater decline in eGFR (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Renal hyperfiltration in acromegaly tends to normalize following treatment, with a more rapid response observed in patients who undergo surgery. Chronic kidney disease is highly prevalent in acromegaly and is closely linked to diabetes, which further contributes to the increased cardiovascular risk seen in these individuals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11102-025-01520-5","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T15:21:24Z","timestamp":1746544884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Kidney function in acromegaly: evidence from a long-term observational study"],"prefix":"10.1007","volume":"28","author":[{"given":"Giona","family":"Castagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cassibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Costi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Alberto","family":"Lanterna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Mirco","family":"Sicignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"2","key":"1520_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/er.2013-1071","volume":"35","author":"P Kamenicky","year":"2014","unstructured":"Kamenicky P, Mazziotti G, Lombes M, Giustina A, Chanson P (2014) Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35(2):234\u2013281","journal-title":"Endocr Rev"},{"issue":"4","key":"1520_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-16-0242","volume":"175","author":"S Fujio","year":"2016","unstructured":"Fujio S, Takano K, Arimura H, Habu M, Bohara M, Hirano H et al (2016) Treatable glomerular hyperfiltration in patients with active acromegaly. Eur J Endocrinol 175(4):325\u2013333","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1520_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.devcel.2017.09.011","volume":"43","author":"N Kirsch","year":"2017","unstructured":"Kirsch N, Chang LS, Koch S, Glinka A, Dolde C, Colozza G et al (2017) Angiopoietin-like 4 is a Wnt signaling antagonist that promotes LRP6 turnover. Dev Cell 43(1):71\u201382 e6","journal-title":"Dev Cell"},{"issue":"1","key":"1520_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11102-023-01370-z","volume":"27","author":"H Bostan","year":"2024","unstructured":"Bostan H, Kizilgul M, Calapkulu M, Kalkisim HK, Topcu FBG, Gul U et al (2024) The prevalence and associated risk factors of detectable renal morphological abnormalities in acromegaly. Pituitary 27(1):44\u201351","journal-title":"Pituitary"},{"issue":"4","key":"1520_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.kint.2023.06.037","volume":"104","author":"S Hong","year":"2023","unstructured":"Hong S, Kim KS, Han K, Park CY (2023) A cohort study found a high risk of end-stage kidney disease associated with acromegaly. Kidney Int 104(4):820\u2013827","journal-title":"Kidney Int"},{"issue":"1","key":"1520_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322","journal-title":"Pituitary"},{"issue":"4","key":"1520_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33(4):278\u2013285","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"1520_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40620-016-0362-x","volume":"30","author":"RJ Glassock","year":"2017","unstructured":"Glassock RJ, Denic A, Rule AD (2017) The conundrums of chronic kidney disease and aging. J Nephrol 30(4):477\u2013483","journal-title":"J Nephrol"},{"key":"1520_CR9","doi-asserted-by":"crossref","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 12(1):7\u201311","DOI":"10.1016\/j.kisu.2021.11.003"},{"issue":"12","key":"1520_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41440-021-00723-0","volume":"44","author":"CS Kim","year":"2021","unstructured":"Kim CS, Kim B, Choi HS, Bae EH, Ma SK, Han KD et al (2021) Cumulative hypertension burden and risk of end-stage renal disease. Hypertens Res 44(12):1652\u20131661","journal-title":"Hypertens Res"},{"issue":"3","key":"1520_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","volume":"106","author":"C Campana","year":"2021","unstructured":"Campana C, Cocchiara F, Corica G, Nista F, Arvigo M, Amaru J et al (2021) Discordant GH and IGF-1 results in treated acromegaly: impact of GH cutoffs and mean values assessment. J Clin Endocrinol Metab 106(3):789\u2013801","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1520_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12020-020-02387-1","volume":"70","author":"V Amodru","year":"2020","unstructured":"Amodru V, Petrossians P, Colao A, Delemer B, Maione L, Neggers S et al (2020) Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege acromegaly survey database. Endocrine 70(1):134\u2013142","journal-title":"Endocrine"},{"issue":"1","key":"1520_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.krcp.2011.12.005","volume":"31","author":"Y Oh","year":"2012","unstructured":"Oh Y (2012) The insulin-like growth factor system in chronic kidney disease: pathophysiology and therapeutic opportunities. Kidney Res Clin Pract 31(1):26\u201337","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"1520_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332","journal-title":"Endocr Rev"},{"key":"1520_CR15","doi-asserted-by":"crossref","unstructured":"Stormann S, Meyhofer SM, Groener JB, Faust J, Schilbach K, Seufert J et al (2024) Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts\u2019 consensus statement. Front Endocrinol (Lausanne). 2024 Feb 9:15:1348990.","DOI":"10.3389\/fendo.2024.1348990"},{"issue":"7","key":"1520_CR16","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney Disease - A systematic review and Meta-Analysis. PLoS ONE 11(7):e0158765","journal-title":"PLoS ONE"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01520-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:20:06Z","timestamp":1751397606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01520-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"24 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Data collection and analysis were approved by an appropriate Institutional Review Board of the local ethical committee. The study was performed in accordance with the Helsinki Declaration of 1964 (and its later amendments) and Good Clinical Practice Guidelines and agreed with national regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants for both participation in the study and publication of the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}}],"article-number":"56"}}